Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kintara Therapeutics, Inc. KTRA
$3.16
-$0.02 (-0.63%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
5431898.00000000
-
week52high
20.00
-
week52low
2.70
-
Revenue
0
-
P/E TTM
0
-
Beta
0.93356400
-
EPS
-22.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Dawson James | Neutral | Buy | 16 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 янв 2022 г. |
| Aegis Capital | Buy | Buy | 30 сент 2021 г. |
| HC Wainwright & Co. | Buy | 28 сент 2021 г. | |
| Aegis Capital | Buy | Buy | 03 февр 2021 г. |
| Maxim Group | Hold | Buy | 29 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Brown Dennis M | A | 5302 | 363 | 05 янв 2023 г. |
| Brown Dennis M | A | 246905 | 240087 | 01 авг 2022 г. |
| Praill Anthony Scott | A | 720260 | 720260 | 01 авг 2022 г. |
| Praill Anthony Scott | A | 277273 | 240087 | 01 авг 2022 г. |
| Hoffman Robert E. | A | 1200634 | 1200634 | 01 авг 2022 г. |
| Hoffman Robert E. | A | 455145 | 400145 | 01 авг 2022 г. |
| Brown Dennis M | A | 720260 | 720260 | 01 авг 2022 г. |
| Johnson Laura L. | A | 100000 | 100000 | 01 июл 2022 г. |
| TOTH ROBERT JOSEPH JR | A | 100000 | 100000 | 01 июл 2022 г. |
| SEYMOUR TAMARA A | A | 100000 | 100000 | 01 июл 2022 г. |
Новостная лента
Is Kintara Therapeutics A Hidden Gem?
MarketBeat
30 дек 2022 г. в 01:01
Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.
Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday - Kintara Therapeutics (NASDAQ:KTRA)
Benzinga
15 дек 2022 г. в 11:49
Kintara Therapeutics Inc KTRA shares are trading higher by 24.09% to $9.94 Thursday morning after the company received FDA Orphan Drug Designation (ODD) for VAL-083.
3 Strategies for Buying and Selling Penny Stocks Right Now
PennyStocks
20 окт 2022 г. в 06:00
Can these penny stocks trading tips help your strategy? The post 3 Strategies for Buying and Selling Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
PRNewsWire
21 июн 2022 г. в 08:00
SAN DIEGO , June 21, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the Alliance Global Partners Summer Healthcare Conference.
Why Kintara Therapeutics Shares Are Skyrocketing Today
Benzinga
15 июн 2022 г. в 11:55
Kintara Therapeutics Inc (NASDAQ: KTRA) shares are trading higher by 28.6% to $0.24 after the FDA granted Fast Track Designation to the company's VAL-083. Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an.